Komori
Fuji Pharma (4554) · PolicyRestated

Adoption of the Fair Value Measurement Standard

First written in FY2022-Q1. 3 of 4 entries say "Restated". Latest entry: FY2022.

4entries
1years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2022-Q1 – FY20222022: 42022
Same theme, other companies
Preparing for adoption of accounting standards for fair value measurementA theme 1870 companies write about · 5 as a headwind · 3 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 196 companies compared. The sentences above are computed from all 196.Comparing 200 of the theme's 1911 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2022RestatedAnnual report

    「We adopted the Accounting Standard for Fair Value Measurement and related standards from the beginning of the current consolidated fiscal year and will apply the new accounting policies prescribed by those standards prospectively. There was no impact on the consolidated financial statements.」

    The company continues to disclose its policy for applying the Accounting Standard for Fair Value Measurement and other standards, as well as the absence of any impact on the financial statements.
  2. FY2022-Q3RestatedAnnual report

    「We adopted the Accounting Standard for Fair Value Measurement and other standards from the beginning of the first quarter and will apply the new accounting policies prescribed by those standards prospectively. The adoption had no impact on the quarterly consolidated financial statements.」

    The company continues to disclose its policy for applying the Accounting Standard for Fair Value Measurement and other standards, as well as the absence of any impact on the quarterly consolidated financial statements.
  3. FY2022-Q2RestatedAnnual report

    「We adopted the Accounting Standard for Fair Value Measurement and other standards from the beginning of the first quarter and will apply the new accounting policies prescribed by those standards prospectively. The adoption had no impact on the quarterly consolidated financial statements.」

    The company continues to disclose its policy for applying the Accounting Standard for Fair Value Measurement and other standards, as well as the absence of any impact on the quarterly consolidated financial statements.
  4. FY2022-Q1First statedAnnual report

    「The Accounting Standard for Fair Value Measurement (ASBJ Statement No. 30, 4 July 2019) and related standards have been adopted from the beginning of the first quarter consolidated accounting period. In accordance with the transitional treatment prescribed in Paragraph 19 of the standard and Paragraph 44-2 of the Accounting Standard for Financial Instruments (ASBJ Statement No. 10, 4 July 2019), the new accounting policies prescribed by the standards will be applied prospectively. The adoption has no impact on the quarterly consolidated financial statements.」

    The Accounting Standard for Fair Value Measurement and other standards were applied prospectively from the beginning of the first quarter of the current fiscal year, but the company stated that they had no impact on the quarterly consolidated financial statements.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuji Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Adoption of the Fair Value Measurement Standard | Fuji Pharma Co.,Ltd. (4554) | Komori